SG187455A1 - Rasagiline formulations, their preparation and use - Google Patents

Rasagiline formulations, their preparation and use Download PDF

Info

Publication number
SG187455A1
SG187455A1 SG2013002241A SG2013002241A SG187455A1 SG 187455 A1 SG187455 A1 SG 187455A1 SG 2013002241 A SG2013002241 A SG 2013002241A SG 2013002241 A SG2013002241 A SG 2013002241A SG 187455 A1 SG187455 A1 SG 187455A1
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
rasagiline
coating
talc
ethyl acrylate
Prior art date
Application number
SG2013002241A
Other languages
English (en)
Inventor
Muhammad Safadi
Dannit Licht
Rachel Cohen
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of SG187455A1 publication Critical patent/SG187455A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG2013002241A 2008-01-11 2009-01-09 Rasagiline formulations, their preparation and use SG187455A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1086008P 2008-01-11 2008-01-11

Publications (1)

Publication Number Publication Date
SG187455A1 true SG187455A1 (en) 2013-02-28

Family

ID=40850833

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013002241A SG187455A1 (en) 2008-01-11 2009-01-09 Rasagiline formulations, their preparation and use

Country Status (15)

Country Link
US (1) US20090181086A1 (enExample)
EP (1) EP2234478A4 (enExample)
JP (2) JP5583597B2 (enExample)
KR (1) KR20100107028A (enExample)
CN (1) CN101909438A (enExample)
AU (1) AU2009204454B2 (enExample)
BR (1) BRPI0905680A2 (enExample)
CA (1) CA2711817A1 (enExample)
EA (1) EA201070842A1 (enExample)
IL (1) IL206136A0 (enExample)
MX (1) MX2010007601A (enExample)
NZ (1) NZ586025A (enExample)
SG (1) SG187455A1 (enExample)
WO (1) WO2009089049A1 (enExample)
ZA (1) ZA201004086B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
CA2600011C (en) * 2005-02-23 2015-11-10 Teva Pharmaceutical Industries Ltd. Rasagiline formulations of improved content uniformity
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
US8946300B2 (en) 2006-04-03 2015-02-03 Teva Pharmaceutical Industries, Ltd. Use of rasagilline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
MX2010013875A (es) 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
AU2010341499A1 (en) 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
WO2013055687A2 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
EP2766004A4 (en) 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
BR112015003451A2 (pt) 2012-08-17 2017-07-04 Teva Pharma formulação parentérica de rasagilina
WO2024098098A1 (en) * 2022-11-07 2024-05-16 Natural MedTech Pty Ltd Tryptamine formulations and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
FI955979L (fi) * 1993-06-14 1995-12-13 Janssen Pharmaceutica Nv Jatkuvasti vapauttava, kalvopäällysteinen astemitsoli- ja pseudoefedriinitabletti
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP0966435B1 (en) * 1996-12-18 2005-04-06 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
SI1567152T1 (sl) * 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
US20050220864A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
EP1663167A1 (en) * 2004-07-26 2006-06-07 Teva Pharmaceutical Industries Ltd Dosage forms with an enterically coated core tablet
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
CA2600011C (en) * 2005-02-23 2015-11-10 Teva Pharmaceutical Industries Ltd. Rasagiline formulations of improved content uniformity
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
MX2010013875A (es) * 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
EP2328861A2 (en) * 2008-07-11 2011-06-08 Synthon BV Polymorphs of rasagiline hydrochloride
US20100029987A1 (en) * 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
AU2010341499A1 (en) * 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
AU2011282716A1 (en) * 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2011282720B2 (en) * 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
CN103188933A (zh) * 2010-10-26 2013-07-03 泰华制药工业有限公司 富集氘的雷沙吉兰
JP2014534195A (ja) * 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトルアミド
EP2766004A4 (en) * 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
WO2013055687A2 (en) * 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan

Also Published As

Publication number Publication date
AU2009204454B2 (en) 2015-02-05
JP2011509295A (ja) 2011-03-24
EP2234478A1 (en) 2010-10-06
AU2009204454A1 (en) 2009-07-16
MX2010007601A (es) 2010-08-03
NZ586025A (en) 2012-08-31
US20090181086A1 (en) 2009-07-16
BRPI0905680A2 (pt) 2015-07-07
WO2009089049A1 (en) 2009-07-16
EP2234478A4 (en) 2013-01-23
EA201070842A1 (ru) 2011-04-29
IL206136A0 (en) 2010-11-30
CN101909438A (zh) 2010-12-08
KR20100107028A (ko) 2010-10-04
ZA201004086B (en) 2011-08-31
JP5583597B2 (ja) 2014-09-03
JP2014237668A (ja) 2014-12-18
CA2711817A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
SG187455A1 (en) Rasagiline formulations, their preparation and use
US20120100189A1 (en) Delayed release rasagiline malate formulation
EP2448406B1 (en) Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
AU2005269416B2 (en) Pharmaceutical dosage forms including rasagiline
Sangalli et al. Different HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery system: a study on process parameters and in vitro performances
US20120034274A1 (en) Pharmaceutical composition comprising one or more fumaric acid esters
AU2010289022B2 (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
DK2729134T3 (en) COMPOSITIONS AND PROCEDURES TO OVERCOME RESISTANCE TO TRAMADOL
KR20110116027A (ko) 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 의약 포뮬레이션
US20190224130A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
CN101495099A (zh) 包含去氧肾上腺素的持续释放的药物剂型
Varum et al. Targeted colonic release formulations of mesalazine–A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis
KR20160060768A (ko) 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손
US20220175766A1 (en) Compositions and methods of treatment
US8277842B1 (en) Enteric-coated HT-2157 compositions and methods of their use
EP2405754A1 (en) Modified release pharmaceutical compositions of buprenorphine
CN113597302A (zh) 一种包括埃索美拉唑或其药学上可接受的盐并具有双重释放特性的药物组合物
CN103315962A (zh) 一种坦索罗辛缓释微丸制剂及其制备方法
Hussain et al. Duloxetine hydrochloride delayed release pellets prepared by suspension layer method
CN108066297A (zh) 治疗老年痴呆症的定位释放美金刚口腔崩解片组合物
CA3268121A1 (en) Stable tablet-in-tablet composition for nausea and vomiting during pregnancy
Krishan FORMULATION AND OPTIMIZATION OF SUSTAINED RELEASE TABLETS OF TRAMADOL AND DALFAMPRIDINE BY FACTORIAL DESIGN MODEL
Yadav Formulation development of oxybutynin chloride controlled release tablet
Nasiri Development and In-Vitro Characterization of Extended Release Pellets of Itopride Hydrochloride